A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia

Journal of Urology

Volumn 160, Issue 5, 1998, Pages 1701-1706

  Narayan, Perinchery ^a,b   Tewari, Ashutosh ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Drug evaluation; Drug therapy; Placebos; Prostatic hypertrophy

Indexed keywords

PLACEBO; TAMSULOSIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; URINE FLOW RATE; VERTIGO;

EID: 0013639611     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62386-3     Document Type: Article

References (22)

1. Raz, S., Zeigler, M. and Caine, M.: Pharmacological receptors in the prostate. Brit. J. Urol., 45: 663, 1973.
2. Caine, M., Pfau, A. and Perlberg, S.: The use of alpha-adrenergic blockers in benign prostatic obstruction. Brit. J. Urol., 48: 255, 1976.
3. McConnell, J. D., Barry, M. J., Bruskewitz, R. C., Bueschen, A. J., Denton, S. E., Holtgrewe, L. H., Lange, J. L., McClennan, B. L. and Mebust, W. K.: Benign prostatic hyperplasia: diagnosis and treatment. In: Clinical Practice Guideline. Rockville, Maryland: Agency for Health Care Policy and Research (AHCPR), vol. 8, pp. 1-17, 1985.
4. Pfizer Cardura BPH indication cleared February 6. The Pink Sheet, 57, T&G-1, Feb. 13, 1995.
5. Fawzy, A., Braun, K., Jewis, G. P., Gaffhey, M., Ice, K. and Dias, N. for the Multicenter Study Group: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J. Urol., 154: 105, 1995.
6. Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., Padley, R. J. and the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. New Engl. J. Med., 335: 533, 1996.
7. Yamada, S., Tanaka, C., Kimura, R. and Kawabe, K.: Alpha 1-adrenoceptors in human prostate: characterization and binding characteristics of alpha 1-antagonists. Life Sci., 54: 1845, 1994.
8. Chapple, C. R.: Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur. Urol., 29: 129, 1996.
9. Chapple, C. R., Wyndaele, J. J., Nordling, J., Boeminghaus, F., Ypma, A. F., Abrams, P. and European Tamsulosin Study Group: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur. Urol., 29: 155, 1996.
10. Wilde, M. I., and McTavish, D.: Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs, 52: 883, 1996.
11. Gillenwater, J. Y., Conn, R. L., Chrysant, S. G., Roy, J., Gaffney, M., Ice, K. and Diaz N. for the Multicenter Study Group: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind placebo controlled, dose response multicenter study. J. Urol., 154: 110, 1995.
12. Lepor, H., Auerbach, S., Puras-Baez, A., Narayan, P., Soloway, M., Lowe, F., Moon, T., Leifer, G. and Madsen, P.: A randomized, placebo controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J. Urol., 148: 1467, 1992.
13. Roehrborn, C. G., Oesterling, J. E., Auerbach, S., Kaplan, S. A., Lloyd, L. K., Milam, D. F., Padley, R. J. and the HYCAT Investigator Group: The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology, 47: 159, 1995.
14. Schulman, C. C., Cortvriend, J., Jonas, U., Lock, T. M., Vaage, S., Speakman, M. J. and the European Tamsulosin Study Group: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur. Urol., 29: 145, 1996.
15. Debruyne, F. M., Witjes, W. P., Fitzpatrick, J., Kirby, R., Kirk, D., Prezioso, D. and the ITT Group: The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Eur. Urol., 30: 369, 1996.
16. Abrams, P., Schulman, C. C., Vaage, S. and The European Tamsulosin Study Group: Tamsulosin, a selective alpha 1C-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Brit. J. Urol., 76: 325, 1995.
17. Kawabe, K., Ueno, A., Takimoto, Y., Aso, Y., Kato, H. and YM617 Clinical Study Group: Use of an α1-blocker, YM-617, in the treatment of benign prostatic hypertrophy. J. Urol., 144: 908, 1990.
18. Kawabe, K.: Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Brit. J. Urol., suppl., 76: 63, 1995.
19. Okada, H., Kawaida, N., Ogawa, T., Arakawa, S., Matsumoto, O., Kamidono, S. and The Kobe University YM617 Study Group: Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. Scand. J. Urol. Nephrol., 30: 379, 1996.
20. Kenny, B. A., Miller, A. M., Williamson, I. J., O'Connell, J., Chalmers, D. H. and Naylor, A. M.: Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Brit. J. Pharmacol., 118: 871, 1996.
21. Lepor, H., Tang, R., Kobayashi, S., Shapiro, E., Forray, C., Wetzel, J. M. and Gluchowski, C.: Localization of the α 1A-adrenoceptor in the human prostate. J. Urol., 154: 2096, 1995.
22. Chapple, C. R., Aubry, M. L., James, S., Greengrass, P. M., Burnstock, G., Turner-Warwick, R. T., Milroy, E. J. and Davey, M. J.: Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Brit. J. Urol., 63: 487, 1989.